-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 9, 2021, Pfizer/BioNTech jointly announced that the mRNA new crown vaccine BNT162b2 has obtained positive results in the ongoing third-dose enhanced vaccination trial
The press release pointed out that data from a paper recently published in the journal Nature showed that in laboratory studies, the immune serum obtained shortly after the second vaccination of BNT162b2 had a significant effect on the Delta variant (b.
The press release pointed out that although the two companies believe that the third dose of BNT162b2 may maintain a high level of protection against all currently tested virus mutants (including Delta variants), they remain vigilant and are developing a new crown vaccine.
Reference materials:
[1] Pfizer and BioNTech Provide Update on Booster Program in Light of the Delta-Variant.